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Nifedipine versus fosinopril in uninephrectomized diabetic rats. Anti-
hypertensive agents have been shown to exert inequivalent effects on
glomerular injury in experimental renal disease models. To compare the
consequences of dissimilar antihypertensive regimens on the develop-
ment of diabetic glomerulopathy, studies were performed in three
groups of uninephrectomized moderately hyperglycemic diabetic rats.
One group (DM) received no therapy except insulin. The remaining
groups received insulin and either the angiotensin I converting enzyme
inhibitor, fosinopril (FOS), or the calcium channel blocker, nifedipine
(NIF). Both drugs lowered blood pressure comparably. At four to eight
weeks, DM rats exhibited elevation of the single nephron glomerular
filtration rate (SNGFR), due to elevations of the glomerular capillary
plasma flow rate (QA) and the glomerular capillary hydraulic pressure(P0). Neither NIF nor FOS affected values for SNGFR or QA.
However, while FOS lowered GC and increased Kf, NIF did not affect
these parameters. In longer term (8 month) studies, DM rats exhibited
progressive albuminuria and glomerular sclerosis. FOS markedly lim-
ited development of albuminuria and glomerular injury, but NIF was
ineffective in limiting either parameter of glomerular injury. Thus, in
contrast to the beneficial effects of converting enzyme inhibitors,
chronic calcium channel blockade with nifedipine fails to limit P0c or
glomerular injury in diabetic rats. These findings lend further support to
the concept that different classes of antihypertensive agents are not
equally effective in protecting against diabetic glomerulopathy.
Systemic hypertension is an important risk factor for the
progression of diabetic glomerulopathy [1], and effective con-
trol of systemic blood pressure may slow the loss of renal
function [2]. However, recent experimental and clinical obser-
vations suggest that all antihypertensive regimens may not
prove equally successful in retarding glomerular injury. Studies
in animal models of diabetes have indicated that angiotensin I
converting enzyme inhibitor (CEI) therapy is extremely effec-
tive in preventing the development of albumiriuria and glomer-
ular injury [3—5], while other antihypertensive regimens such as
combination vasodilator/diuretic therapy [4] or the calcium
channel blocker, verapamil [5], may be less successful. Clinical
studies have suggested that antihypertensive classes may differ
in their ability to reduce albuminuria in diabetic patients [6—10],
perhaps suggesting differential effects on intraglomerular hemo-
dynamics. In this study, we sought to examine the hemody-
namic and structural consequences of antihypertensive therapy
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with the calcium antagonist nifedipine in a rat model of diabe-
tes, and to compare them with those of CEI.
Methods
Three groups of adult male Munich-Wistar rats, with initial
weights of 280 to 300 g, were studied. All rats were initially
subjected to removal of the right kidney under Brevital anes-
thesia (50 mg/kg i.p.), and two weeks later were made diabetic
by intravenous tail injection of streptozotocin (STZ, Sigma
Chemical Co., St. Louis, Missouri, USA), 60 mg/kg body
weight. This combined approach was chosen to hasten the
development of diabetic glomerulopathy, so that extensive
damage could be expected in untreated rats in a time period
about half that required in diabetes alone. Two days later, the
diabetic state was confirmed by measurement of tail blood
glucose (BG) level using a reflectance meter (Miles Ames Div.,
Miles Laboratories, Inc., Elkhart, Indiana, USA). Diabetic rats
received daily evening injections of ultralente insulin (Iletin I,
Eli Lilly & Co., Indianapolis, Indiana, USA), in doses individ-
ually adjusted to maintain BG levels between 200 and 400 mg/dl.
BG levels were monitored at least once a week. All rats were
fed standard rat chow (Rodent Laboratory Chow 5001, Ralston
Purina Co., Richmond, Indiana, USA) ad libitum.
One diabetic group (DM) received no therapy other than
insulin. A second group (DM/FOS) was treated with insulin and
with the CEI fosinopril (E.R. Squibb & Sons, Inc., Princeton,
New Jersey, USA), administered in the drinking water at a
concentration of 200 mg/liter. The third group (DM/NIF) re-
ceived the calcium antagonist nifedipine (NIF) (Pfizer Labora-
tories, New York, New York, USA), administered at a dose of
5 mg s.c. b.i.d. This route of administration was chosen after
pilot studies indicated inability to reduce systemic blood pres-
sure when nifedipine was supplied in the food. Doses of all
antihypertensive regimens were adjusted as needed to maintain
the systolic blood pressure in the range of 100 to 120 mm Hg,
representing a modest reduction below values seen in the DM
rats receiving only insulin. Frequent interim blood pressure
measurements were performed to ensure continuing blood
pressure control; occasionally doses were adjusted in individual
rats to maintain the desired blood pressure. Extensive pilot
testing established that doses exceeding these levels resulted in
excessive hypotension (systolic blood pressure < 100 mm Hg),
while doses less than those reported resulted in inadequate
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blood pressure lowering (systolic blood pressure > 130 mm
Hg).
Subsets of rats in each group underwent whole kidney and
glomerular hemodynamic studies at four to eight weeks after
STZ injection. The long-term groups were followed with bi-
monthly determinations of systolic blood pressure (SBP) by the
tail cuff method, and of 24-hour urinary albumin excretion rates
(UalbV). At eight months, the rats were sacrificed for examina-
tion of renal morphology.
Micropuncture studies
Following confirmation of desired BG levels, rats were anes-
thetized with mactin (100 mg/kg i.p.) and placed on a temper-
ature-regulated table. The left femoral artery was catheterized,
and a baseline collection of blood was obtained for measure-
ment of hematoci-it (Hct) and inulin "blank". This arterial
catheter was used for subsequent periodic blood sampling and
estimation of mean arterial pressure (AP) via an electronic
transducer connected to a direct-writing recorder. After trache-
ostomy, venous catheters were inserted for infusions of inulin
and plasma. Intravenous infusions of rat plasma, and 10% inulin
solution in 0.9% NaCI, were started at rates of 6.0 and 1.2 ml/hr,
respectively. The left ureter was catheterized for urine collec-
tion, and the left kidney exposed and suspended on a lucite
holder, with its surface illuminated and bathed with isotonic
saline.
Since the plasma volume of rats prepared for micropuncture
is reduced by —20% [11], euvolemia was maintained using the
following protocol. Isoncotic rat plasma was infused at 6 mI/hr
in a total amount equal to 1% of the body weight, followed by
a reduction in infusion rate to 1.6 ml/kg/hr, to maintain the Hct
constant. These diabetic rats received extra saline to match the
excessive urinary losses during the procedure, if initial urine
flow rates proved excessive.
For calculation of SNGFR, exactly timed samples of tubule
fluid were collected for determination of flow rate and inulin
concentration. Samples of efferent arteriolar blood were ob-
tained for determination of protein concentration. Coincident
with these collections, arterial blood was obtained for determi-
nation of Hct and plasma concentrations of inulin and protein,
and 10 to 20 minute urine collections were obtained for deter-
mination of flow rate and inulin concentration. These measure-
ments permitted calculation of glomerular filtration rate (GFR)
(inulin clearance) by standard formulas. Time-averaged hydrau-
lic pressures were measured in surface glomerular capillaries,
proximal tubules, and efferent arterioles with a servo-null
micropipette transducer system (Instrumentation for Physiol-
ogy and Medicine, San Diego, California, USA). Colloid os-
motic pressure of plasma entering and leaving glomerular
capillaries was estimated from values for protein concentration
in femoral arterial (representing afferent arteriolar) and efferent
arteriolar plasma using the equation derived by Deen et al [121.
These estimates of pre- and post-glomerular plasma protein
concentration permit calculation of SN filtration fraction, gb-
merular capillary ultrafiltration coefficient (Kr), and afferent and
efferent arteriolar blood flow rates and resistances, using equa-
tions previously described [12]. At the end of the procedure,
blood was obtained for determination of glycosylated hemoglo-
bin (HbA1), after which the kidneys were perfusion-fixed for
morphologic studies.
Morphology
Kidneys were perfused at the measured systolic arterial
pressure for two to three minutes with 1.25% glutaraldehyde in
0.1 M sodium cacodylate buffer (pH 7.4). After perfusion
fixation, kidney weights were recorded, and two midcoronal
slices of 2 to 3 mm thickness were processed for light micro-
scopic examination. Three-micrometer-thick paraffin sections
were stained with hematoxylin and eosin and by the periodic
acid Schiff (PAS) reaction. The extent of glomerular damage
was determined on PAS-stained slides by counting on two
coronal sections all glomerular profiles with segmental or global
collapse of capillaries, with or without associated hyalin depo-
sition and adhesion of the tuft to Bowman's capsule. The extent
of glomerular sclerosis was expressed as the percentage of
glomeruli with sclerotic lesions.
—
The average glomerular tuft volume (VG) for each animal was
determined by the procedure described by Weibel [13]. For this
purpose, the mean glomerular random cross-sectional area (AG)
was determined on 50 systematically sampled glomerular tuft
profiles by point counting at a final magnification of 200x using
a 361-point ocular grid covering a 369,664 m2 microscopic
field. V0 was then calculated as V0 = (/3/sc)(A0)312, where p =
1.38 and ic 1.1 are shape and size distribution coefficients,
respectively [13, 14].
Analytical
The volume of fluid collected from individual proximal tu-
bules was estimated from the length of the fluid column in a
constant bore capillary tube of known internal diameter. The
tubule fluid inulin concentration was measured by a microfbuo-
rescence method [15]. Inulin concentrations in plasma and urine
were measured using a macro-anthrone method [16]. Protein
concentrations were determined using a fluorometric method
[17]. Urinary albumin concentration was measured by radial
immunodiffusion [18]. By this method, the assay is sensitive to
a level of 1.25 jig/mI, with a standard deviation of less than 2%
of the mean [IS]. Glycosylated hemoglobin was determined by
affinity column chromatography (Glyco-Gel B, Pierce Chemical
Co., Rockford, Illinois, USA) [19].
Statistical
Statistical analysis was performed by one-way analysis of
variance followed by computation of modified t values for three
preplanned pairwise comparisons according to the method of
Bonferroni [20]. Statistical significance was defined as P < 0.05.
All values represent means 5EM.
Results
General
Serial values for body weight, SBP, and BG are depicted in
Figures 1 to 3. There were no differences among the groups in
body growth (Fig. 1). Comparable hyperglycemia was main-
tained in all groups (Fig. 2). Values for awake systolic blood
pressure were modestly and equivalently reduced by FOS and
NIP as compared to DM rats, but did not differ between
DM/FOS and DM/NIF groups (Fig. 2). Studies in an additional
group of rats (N = 6) receiving the vehicle for nifedipine (that is,
placebo injections) did not differ from those in DM rats,
confirming that the vehicle did not influence SBP. Pilot studies
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Fig. 1. Body weight. Serial values for body weight in diabetic rats (N =
9), and diabetic rats treated with fosinopril (DM/FOS, N = 12) or
nifedipine (DM/NIF, N = 13). There were no significant differences
among groups. Values are means SEM.
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Fig. 2. Blood glucose and systolic blood pressure. Serial values for
blood glucose (BG) and systolic blood pressure (SBP) in diabetic rats
(DM), and diabetic rats treated with fosinopril (DM/FOS) or nifedipine
(DM/NIF). All rats exhibited comparable hyperglycemia over time; BG
did not differ among groups. Values for SBP were modestly but
significantly and comparably lowered in DM/FOS and DM/NIF rats as
compared to DM rats. Values are means SEM; N as per Fig. 1.
of systolic blood pressure performed in the evening confirmed
continuing blood pressure control in all groups. Insulin require-
ments did not differ among groups. Random measurements
indicated that food and water intake were supranormal in these
diabetic rats, but did not differ among the groups. Mean values
for 24-hour urine output (DM: 26 4; DM/FOS, 34 8;
DM/NIF, 40 6 mi/day) were also above the normal range, but
did not differ among the groups.
Time, months of diabetes
Fig. 3. Albuminuria. Serial values for 24-hour urinary albumin excre-
tion (UabV) in diabetic rats (DM), and diabetic rats treated with
fosinopril (DM/FOS) or nifedipine (DM/NIF). DM rats exhibited in-
creasing UaIbV over time; progressive albuminuria was markedly lim-
ited with FOS (P < 0.05 vs. DM and DM/NIF at all time points), but not
with NIF(P >0.05 vs. DM). Values are means SEM; Nas per Fig. 1.
Systemic and renal hemodynamic parameters
Mean values for systemic and whole kidney parameters in
rats subjected to micropuncture study are summarized in Table
I. Body weight was similar on average in all groups. Average
values for left kidney weight and mean glomerular volume were
above the normal range [3, 4] in all groups, but did not differ
among the groups. Comparable hyperglycemia, reflected by
both blood glucose and HbAIC levels, was evident in all groups.
Systemic Hct did not differ among groups. Average values for
GFR were above the normal range in all groups, but did not
differ from one group to another.
Values for AP, single nephron GFR, and glomerular and
tubule microcirculatory parameters at four to eight weeks of
diabetes are summarized in Table 2. Values for AP were normal
in DM rats, whereas AP was significantly and comparably
reduced in rats receiving FOS or NIF. As in previous studies in
diabetic rats [3, 41, the moderately hyperglycemic diabetic rats
exhibited single nephron hyperfiltration, due to elevations in
both the glomerular capillary plasma flow rate (QA) and glomer-
ular capillary hydraulic pressure ()• Reductions in both
afferent (RA) and efferent (RE) arteriolar resistances allowed the
increase in QA, and a disproportionate fall in RA relative to RE
contributed to the increase in P0g. The magnitude of these
changes was similar to those found in two-kidney diabetic rats
[3, 41, and exceeded those induced by uninephrectomy alone
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SNFF
PGC PT
Group mm Hg
DM 118± 5 91± 7 0.27±0.01 341 60±1 18±1 12±1 47± 1
(N =8)
DM/FOS 106 3 90 10 0.22 0.01 401 37 49 2 18 1 13 1 36 ia
(N = 8)
DM/N!F 106 2 96 10 0.26 0.01 381 43 60 20 1 16 45 2b
(N = 9)
Values are means SEM. Abbreviations are: AP, mean arterial pressure; SN, single nephron; GFR, glomerular filtration rate; FF, filtration
fraction; QA glomerular capillary plasma flow rate; P, mean glomerular capillary hydraulic pressure; P, efferent arteriolar hydraulic pressure;
T, proximal tubule hydraulic pressure; P, mean transcapillary hydraulic pressure gradient; RA and RE, afferent and efferent arteriolar
resistances; CA and CE, afferent and efferent arteriolar plasma protein concentration; "A and "E' afferent and efferent colloid osmotic pressures;
K1, glomerular capillary ultrafiltration coefficient.
a < 0.05 vs. DM
b P < 0.05 vs. DM/FOS
Table 2. Continued
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[211, suggesting that the hemodynamic changes were due, in
large part, to the diabetic state.
Despite the reduction in renal perfusion pressure, neither
antihypertensive regimen significantly affected average SNGFR
or QA values. However, there were prominent differences in the
effects of these regimens on P0. As in previous studies of CEI
in diabetic rats [3, 4], fosinopril effectively controlled glomeru-
lar capillary hypertension. Glomerular pressure was lowered by
the reduction in perfusion pressure, but also by a significant
reduction in RE, efferent arteriolar resistance. In contrast,
despite equivalent AP reduction, rats receiving nifedipine ex-
hibited average values for which remained at the same high
levels seen in diabetic rats receiving no antihypertensive ther-
apy. Values for P, the glomerular transcapillary hydraulic
pressure difference, were also higher in DM/NIF rats, despite a
slight increase in average values for proximal tubule pressure,
than in DM/FOS rats. Values for the glomerular capillary
ultrafiltration coefficient, Kf, were significantly elevated in
DMIFOS rats as compared to DM rats, with lesser and insig-
nificant increases in Kf seen in DM/NIF rats. There were no
significant differences in arteriolar protein concentrations or
colloid osmotic pressures among the groups. Thus, neither
antihypertensive drug significantly influenced the single neph-
ron hyperfiltration and hyperperfusion of diabetes, whereas
fosinopril, but not nifedipine, normalized glomerular capillary
pressure, and increased Kf.
Long-term studies
Serial studies confirmed maintenance of equivalent hypergly-
cemia in all groups, and comparable blood pressure reduction in
the groups receiving antihypertensive therapy (Fig. 2). Final
determinations of systemic and renal parameters at eight
months of diabetes are summarized in Table 3. Systolic blood
pressures remained equivalently reduced in the treated groups.
As in the studies performed early in diabetes, all groups
exhibited values for left kidney weight and glomerular volume
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Table 1. Systemic and whole kidney parameters at four to eight weeks
Body
wt
Left kidney
wt Hct
AP
mm Hg
SNGFR
ni/mm
Table 2. Systemic and glomerular hemodynamic parameters
QA
ni/mm
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DM
(N = 9)
DM/FOS 118 4b 340 11 2.72 0.10 2.97 0.13 326 7 9.4 0.6 32 7"(N = 12)
DMINIF 118 4" 361 14 3.10 0.14 3.25 0.19 285 21 8.2 0.3 136 26C
(N = 13)
________ ________________________ _______
Values are means SEM. Abbreviations are: SBP, systolic blood pressure; V0. mean glomerular volume;
glycosylated hemoglobin; UalbV, 24-hr urinary albumin excretion; FGS, focal and segmental glomerular sclerosis.
a N = 7 (DM), 6 (DM/FOS), 9 (DM/NIF)b P < 0.05 vs. DM
P < 0.05 vs. DM/FOS
which were above the normal range, but there were no differ-
ences among the groups. Comparable hyperglycemia was re-
flected in final BG determinations, as well as in values for
HbAIC obtained at the time of sacrifice.
Despite equivalent hyperglycemia and blood pressure, the
long-term outcomes in the treated groups differed substantially.
Serial values for UV are depicted in Figure 3, and final values
in Table 3. Diabetic rats receiving only insulin exhibited signif-
icant elevations in UalbV as early as one month after induction
of diabetes, and UalbV increased markedly over time. Fosino-
pril therapy very effectively limited the development of UaIbV.
In contrast to the protective effect of CEI, however, rats
receiving nifedipine exhibited elevated values for UaIbV early in
the course, and marked escalation over time, so that values at
the end of the study were as high as those in DM rats not
receiving antihypertensive therapy.
Structural changes
The extent of focal and segmental glomerular sclerosis (Table
3, Fig. 4) generally correlated with patterns of albuminuria. The
diabetic state was associated with marked glomerular injury,
with sclerosis involving 19.8 2.9% of glomeruli. As in
previous studies using CEI therapy in diabetic rats [3, 4],
sclerosis was markedly lessened in DM/FOS rats, averaging
only 5.3 1.4% of glomeruli. In contrast, morphologic assess-
ment in DM/NIF rats indicated absence of protection, with
values for glomerular sclerosis (16.3 2.3%) being similar to
those seen in the DM rats not receiving antihypertensive
therapy. Thus, converting enzyme inhibition offered protection
against development of glomerular injury, while calcium chan-
nel blockade was ineffective.
Discussion
Both antihypertensive regimens employed in this study effec-
tively lowered systemic blood pressure, thereby enabling com-
parison of the effects of these different classes of antihyperten-
sive therapy. Despite comparable effects on systemic blood
pressure, and absence of any difference in metabolic control,
the long-term sequelae of these therapeutic regimens differed
substantially. In accord with many previous studies of CEI
therapy in diabetic [3—51 and other [22—24] experimental mod-
els, converting enzyme inhibition with fosinopril very effec-
tively reduced albuminuria at every determination, and signifi-
cantly limited the development of glomerular sclerosis. Of note,
however, were the findings with the calcium antagonist nife-
dipine, which afforded no protection against the development of
albuminuria or glomerular injury. Calcium antagonists are
widely used in the treatment of hypertension, because of their
effective hypotensive potency and relative absence of troubling
metabolic side effects. However, studies using this class of
agents to examine progression of experimental renal disease
have yielded conflicting results. In the remnant kidney model, it
has been reported that verapamil in non-hypotensive doses
affords protection [25], while others have found hypotensive
Table 3. Systemic and renal parameters at eight months of diabetes
Body Left kidney
SBP
mm Hg
Wta wta
x
V0
1O p.m3
BG
mg/dl
HbAIC
%
UaIbV
mg/day
FGS
%g
145 5 380 6 2.75 0.07 3.40 0.19 312 14 8.1 0.2 113 18 19.8 2.9
5.3 1.4"
16.3 2.3'
BG, blood glucose; HbA,C,
25
20
Q..
- 15(I,
LI
10
5
Fig. 4. Focal glomerular sclerosis. Mean values for focal glomerular
sclerosis (FGS) in diabetic rats (DM, N = 7), and diabetic rats treated
with fosinopril (DM/FOS, N = 6) or nifedipine (DM/NIF, N = 9). FGS
was substantial in DM and DM/NIF rats, but markedly limited in
DM/FOS rats. Values are means SEM. < 0.05 vs. DM; tP < 0.05
vs. DM/FOS.
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doses ineffective [26]. Nifedipine and other dihydropyridine
derivatives have been more successful in preventing glomerular
injury in rats with systemic hypertension and progressive renal
disease [24, 28—30], though not without exception [27, 31]. Of
the third clinically-available class of calcium antagonists, dilt-
iazem and its derivatives have also proven variable with respect
to renal protection [32—34]. Our results further reinforce the
conclusion that dihydropyridine calcium antagonists may offer
inconsistent protective ability, in this case failing to protect in
the setting of experimental diabetes.
It seems likely that failure to control glomerular capillary
hypertension explains the absence of structural protection
afforded by nifedipine. Numerous previous studies in diabetic
[3, 4] and other [22, 23] experimental models have confirmed
the association between reduction of glomerular pressure, and
amelioration of glomerular injury; antihypertensive regimens
which fail to afford continuing control of glomerular hyperten-
sion have frequently not been successful [4, 22], For example,
previous studies in diabetic rats indicated that the combination
of reserpine, hydralazine and hydrochlorothiazide lowered P6
and UalbV early in the course, but failed to provide sustained
reduction in either parameter, and thus was less effective than
captopril in reducing injury [4]. Fosinopril, like other convert-
ing enzyme inhibitors [3, 4], effectively lowered P0 by reduc-
ing both AP and R. The reduction in efferent arteriolar
resistance, in turn, is most likely due to interference with the
action of angiotensin lion this vascular segment; indeed, recent
studies using a specific angiotensin II receptor antagonist have
found similar hemodynarnic effects in diabetic rats [35]. The
effects of nifedipine on P0 have proven variable, with this
regimen controlling glomerular hypertension in some experi-
mental models [24] but not in others [281. Though it has been
postulated that calcium antagonists interfere with the action of
angiotensin II, failure of nifedipine to reduce R in this study
suggests that such a mechanism is not prominent in efferent
arteriolar microvascular regulation in vivo.
it has been reported that reducing blood pressure with
nifedipine lessens glornerular sclerosis in mineralocorticoid-salt
rats without reducing POC [28]; however, our findings in exper-
imental diabetes clearly indicate no protective effect of nife-
dipine in this model. As in our previous studies in diabetic rats
[4], we also found no correlation between renal or glomerular
enlargement and development of injury. In the former study,
both captopril and combination therapy resulted in similar
limitations in glomerular volume, as compared to diabetic rats
not receiving antihypertensive therapy [41. In the present study,
neither antihypertensive regimen limited structural growth, and
thus effects on growth cannot be invoked to explain the
differences between CEI and calcium channel blocker therapy
in limiting injury. The differences between these studies regard-
ing effects of antihypertensive therapy on glomerular volumes
could relate to the differing duration of study, and/or to added
hypertrophic influence of uninephrectomy in the present study.
Other modulating factors, such as changes in size of specific
intraglomerular components, cannot be excluded, though no
such differences were qualitatively apparent. Finally, the role of
serum cholesterol was not specifically addressed in this study;
however, the degree of hyperlipidemia in this model is modest,
and neither class of antihypertensive drugs is generally associ-
ated with consistent changes in serum lipid levels.
Long-term clinical trials comparing ability of antihyperten-
sive regimens to slow progression of diabetic nephropathy are
not yet conclusive. Relatively short-term studies examining the
influence of antihypertensive therapy with calcium antagonists
on UaIbV in diabetic patients have also provided somewhat
conflicting results. Both Demarie and Bakris [9] and Mimran et
at [8] found that while CEI significantly reduced UalhV in
diabetic patients, equivalent reductions in blood pressure with
nifedipine resulted in actual increases in UlbV. This augmen-
tation of UajbV may not be found with all calcium antagonists,
given recent reports of reductions in UUIbV with diltiazem [7, 9]
and of the ability of verapamil to enhance the antiproteinuric
effect of CEI [10] in diabetic patients. Since both diltiazem and
verapamil normalize P0 in remnant kidney rats [36], their
antiproteinuric efficacy in diabetic patients could relate to
similar salutory hemodynamic effects. In contrast to these
findings, other studies in patients with incipient nephropathy
and minimal albuminuria [37], and in patients with type II
diabetes [38], have noted equivalent effects on UlbV in com-
parison trials of nifedipine and CU therapy. At present, expla-
nations for these disparate findings with nifedipine in diabetic
patients are lacking. However, these conflicting reports con-
trast with the almost uniformly beneficial results of studies
using CLI therapy. Converting enzyme inhibitors have been
shown to reduce Ua)bV in numerous clinical studies, in patients
ranging from early diabetes with normoalbuminuria or microal-
buminuria, to those with advanced diabetic nephropathy [39].
In summary, the long-term consequences of fosinopril and
nifedipine were compared in moderately hyperglycemic, unine-
phrectomized diabetic rats. Blood pressure was modestly and
comparably reduced in both treated groups as compared to
diabetic rats receiving only insulin. Neither regimen affected
the single nephron hyperfiltration or hyperperfusion of diabe-
tes. However, while fosinopril effectively controlled glomerular
hypertension, nifedipine did not. Reduction of both systemic
and glomerular pressures with fosinopril was associated with
striking protection against development of albuminuria and
glomerular injury, whereas reducing systemic but not glomeru-
lar pressure with nifedipine afforded no renal protection. These
findings suggest that differing antihypertensive regimens may
not prove equally effective in protecting the diabetic kidney,
and that long-term clinical trials comparing various antihyper-
tensive regimens are needed to define optimal therapy of this
patient population at high risk for development of advanced
nephropathy and end-stage renal disease.
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